Cinacalcet ? Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081740%3A_____%2F10%3A00350402" target="_blank" >RIV/68081740:_____/10:00350402 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cinacalcet ? Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

Popis výsledku v původním jazyce

The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, CaP, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 9.59 to 20.62 9.22. Cinacalcet decreased elevated s-Ca, s-P, CaP, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.

Název v anglickém jazyce

Cinacalcet ? Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

Popis výsledku anglicky

The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, CaP, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 9.59 to 20.62 9.22. Cinacalcet decreased elevated s-Ca, s-P, CaP, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Kidney & Blood Pressure Research

ISSN

1420-4096

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000284644200001

EID výsledku v databázi Scopus

—